连接黏附分子C表达界定小鼠和人类CD138低/阴多发性骨髓瘤细胞群
研究显示连接黏附分子C(JAM-C)在多发性骨髓瘤(MM)细胞中动态表达,与骨髓血管共定位,其上调与经典浆细胞标志物CD138下调呈负相关;在小鼠同基因MM模型中靶向JAM-C可改善MM进展与结局,提示JAM-C可能作为诊断生物标志物和治疗靶点。
要点
- JAM-C在MM细胞中动态表达并与骨髓血管共定位。
- JAM-C上调与CD138下调呈负相关,界定CD138低/阴MM细胞群。
- 小鼠同基因MM模型中靶向JAM-C可改善MM进展与结局。
核心结论
- JAM-C可能不仅作为新的诊断生物标志物,还可能作为MM的治疗靶点。
研究设计与样本
- 研究检测了患者和小鼠骨髓中MM细胞的JAM-C表达与定位,并在小鼠同基因体内MM模型中靶向JAM-C。
主要发现
- JAM-C在骨髓MM细胞中动态表达,并与患者和小鼠骨髓内血管共定位。
- JAM-C上调与经典浆细胞标志物CD138(syndecan-1)下调呈负相关。
- 在小鼠同基因体内MM模型中靶向JAM-C可改善MM进展与结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Deregulation such as overexpression of adhesion molecules influences cancer progression and survival. Metastasis of malignant cells from their primary tumor site to distant organs is the most common reason for cancer-related deaths. Junctional adhesion molecule-C (JAM-C), a member of the immunoglobulin-like JAM family, can homodimerize and aid cancer cell migration and metastasis. Here we show that this molecule is dynamically expressed on multiple myeloma (MM) cells in the bone marrow and co-localizes with blood vessels within the bone marrow of patients and mice. In addition, upregulation of JAM-C inversely correlates with the downregulation of the canonical plasma cell marker CD138 (syndecan-1), whose surface expression has recently been found to dynamically regulate a switch between MM growth in situ and MM dissemination. Moreover, targeting JAM-C in a syngeneic in vivo MM model ameliorates MM progression and improves outcome. Overall, our data demonstrate that JAM-C might serve not only as an additional novel diagnostic biomarker but also as a therapeutic target in MM disease.
引用
- Brandl A, Solimando AG, Mokhtari Z, et al. Junctional adhesion molecule C expression specifies a CD138low/neg multiple myeloma cell population in mice and humans. Blood Adv. 2022. PMID: 34861679. doi:10.1182/bloodadvances.2021004354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。